Market revenue in 2023 | USD 1,295.7 million |
Market revenue in 2030 | USD 1,947.4 million |
Growth rate | 6% (CAGR from 2023 to 2030) |
Largest segment | Inhaled |
Fastest growing segment | Other Allergens |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Inhaled, Drug, Other Allergens, Food |
Key market players worldwide | Rohm Co Ltd, Thermo Fisher Scientific Inc, PerkinElmer, BioMerieux SA, Siemens Healthineers AG ADR, Omega Healthcare Investors Inc, Danaher Corp, Alcon Inc, AbbVie Inc, Sanofi SA, Allergy Therapeutics PLC, Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, Sun Pharmaceutical Industries, Roche Holding AG, Merck & Co Inc, Astellas Pharma Inc, Epigenomics AG |
Inhaled was the largest segment with a revenue share of 49.52% in 2023. Horizon Databook has segmented the Italy allergy diagnostics and therapeutics market based on inhaled, drug, other allergens, food covering the revenue growth of each sub-segment from 2018 to 2030.
Italy’s allergy diagnostics and therapeutics market is projected to grow at a significant rate over the forecast period due to rising cases of allergy in the country. Pollen allergies are highly common in Italy, of which pollinosis is the most common allergic disease.
Growing government initiatives to expand healthcare infrastructure along with increasing investments in R&D activities for developing novel drugs and IVDs for better treatment are fueling the market growth. Some of the common players in the region are Sun Pharmaceutical Industries Ltd, Siemens Healthcare GmbH, and Thermo Fisher Scientific, Inc.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account